SOUTH SAN FRANCISCO, Calif. — March 29, 2023 — Epicrispr Biotechnologies, a leading epigenome engineering company developing therapies to modulate gene expression using ultracompact, non-cutting dCas proteins, today announced that the company will participate in the Guggenheim Healthcare Talks – Genomic Medicine and Rare Disease Days, April 3-4, 2023, in New York, NY. The company will also hold meetings with investors and analysts during the event.
Amber Salzman, Ph.D., Epicrispr Biotechnologies’ chief executive officer, is scheduled to participate in a panel on genomic medicines and rare diseases on Monday, April 3, 2023, from 1:00 – 2:00 p.m. ET.
About Epicrispr Biotechnologies
Epicrispr Biotechnologies is a leading epigenome engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company’s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies leveraging delivery via a single AAV or LNP. Epicrispr Biotechnologies has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypercholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epicrispr.com for more information or follow us on Twitter and LinkedIn.
Investor Contact
Shawn M. Cox
Manager, Investor Relations, Corporate Communications
Epicrispr Biotechnologies
shawn.cox@epic-bio.com
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783